Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Hongkong, Mexico, Switzerland, UK

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.75
AMGN's P/E(ttm) is ranked higher than
74% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. AMGN: 16.75 )
Ranked among companies with meaningful P/E(ttm) only.
AMGN' s P/E(ttm) Range Over the Past 10 Years
Min: 10.4  Med: 16.97 Max: 37.29
Current: 16.75
10.4
37.29
Forward P/E 12.84
AMGN's Forward P/E is ranked higher than
69% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. AMGN: 12.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.75
AMGN's PE(NRI) is ranked higher than
75% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. AMGN: 16.75 )
Ranked among companies with meaningful PE(NRI) only.
AMGN' s PE(NRI) Range Over the Past 10 Years
Min: 10.4  Med: 16.97 Max: 37.39
Current: 16.75
10.4
37.39
Price/Owner Earnings (ttm) 12.75
AMGN's Price/Owner Earnings (ttm) is ranked higher than
79% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. AMGN: 12.75 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AMGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.04  Med: 13.36 Max: 34.29
Current: 12.75
9.04
34.29
P/B 4.15
AMGN's P/B is ranked lower than
59% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. AMGN: 4.15 )
Ranked among companies with meaningful P/B only.
AMGN' s P/B Range Over the Past 10 Years
Min: 1.8  Med: 3.55 Max: 5.21
Current: 4.15
1.8
5.21
P/S 5.60
AMGN's P/S is ranked higher than
69% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. AMGN: 5.60 )
Ranked among companies with meaningful P/S only.
AMGN' s P/S Range Over the Past 10 Years
Min: 3.03  Med: 4.36 Max: 9.11
Current: 5.6
3.03
9.11
PFCF 14.40
AMGN's PFCF is ranked higher than
72% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. AMGN: 14.40 )
Ranked among companies with meaningful PFCF only.
AMGN' s PFCF Range Over the Past 10 Years
Min: 8.85  Med: 13.85 Max: 29.99
Current: 14.4
8.85
29.99
POCF 13.37
AMGN's POCF is ranked higher than
72% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. AMGN: 13.37 )
Ranked among companies with meaningful POCF only.
AMGN' s POCF Range Over the Past 10 Years
Min: 7.3  Med: 12.25 Max: 23.4
Current: 13.37
7.3
23.4
EV-to-EBIT 12.99
AMGN's EV-to-EBIT is ranked higher than
68% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. AMGN: 12.99 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 13.60 Max: 25.8
Current: 12.99
7.4
25.8
EV-to-EBITDA 10.56
AMGN's EV-to-EBITDA is ranked higher than
70% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. AMGN: 10.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 11.00 Max: 21.5
Current: 10.56
6.2
21.5
PEG 0.99
AMGN's PEG is ranked higher than
74% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. AMGN: 0.99 )
Ranked among companies with meaningful PEG only.
AMGN' s PEG Range Over the Past 10 Years
Min: 0.18  Med: 1.09 Max: 3.05
Current: 0.99
0.18
3.05
Shiller P/E 29.94
AMGN's Shiller P/E is ranked higher than
78% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. AMGN: 29.94 )
Ranked among companies with meaningful Shiller P/E only.
AMGN' s Shiller P/E Range Over the Past 10 Years
Min: 17.36  Med: 27.20 Max: 58.54
Current: 29.94
17.36
58.54
Current Ratio 4.44
AMGN's Current Ratio is ranked lower than
52% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. AMGN: 4.44 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 3.27 Max: 4.95
Current: 4.44
1.67
4.95
Quick Ratio 4.16
AMGN's Quick Ratio is ranked lower than
52% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. AMGN: 4.16 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 2.89 Max: 4.58
Current: 4.16
1.4
4.58
Days Inventory 221.69
AMGN's Days Inventory is ranked lower than
76% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. AMGN: 221.69 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 219.41  Med: 300.96 Max: 374.86
Current: 221.69
219.41
374.86
Days Sales Outstanding 50.71
AMGN's Days Sales Outstanding is ranked higher than
62% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. AMGN: 50.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.64 Max: 67.84
Current: 50.71
46.32
67.84
Days Payable 83.62
AMGN's Days Payable is ranked higher than
59% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. AMGN: 83.62 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 54.15  Med: 86.19 Max: 117.72
Current: 83.62
54.15
117.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.13
AMGN's Dividend Yield is ranked higher than
87% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. AMGN: 2.13 )
Ranked among companies with meaningful Dividend Yield only.
AMGN' s Dividend Yield Range Over the Past 10 Years
Min: 0.48  Med: 1.61 Max: 2.19
Current: 2.13
0.48
2.19
Dividend Payout 0.35
AMGN's Dividend Payout is ranked higher than
99% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.33 vs. AMGN: 0.35 )
Ranked among companies with meaningful Dividend Payout only.
AMGN' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.28 Max: 0.36
Current: 0.35
0.14
0.36
Dividend Growth (3y) 29.90
AMGN's Dividend Growth (3y) is ranked higher than
88% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. AMGN: 29.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AMGN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 63.3
Current: 29.9
0
63.3
Forward Dividend Yield 2.53
AMGN's Forward Dividend Yield is ranked higher than
79% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. AMGN: 2.53 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.16
AMGN's Yield on cost (5-Year) is ranked higher than
76% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. AMGN: 2.16 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AMGN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.48  Med: 1.61 Max: 2.19
Current: 2.16
0.48
2.19
3-Year Average Share Buyback Ratio 0.90
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. AMGN: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.5  Med: 4.00 Max: 8.3
Current: 0.9
-7.5
8.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 48.99
AMGN's Price/Tangible Book is ranked lower than
95% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. AMGN: 48.99 )
Ranked among companies with meaningful Price/Tangible Book only.
AMGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.93  Med: 15.34 Max: 73.95
Current: 48.99
4.93
73.95
Price/Projected FCF 1.07
AMGN's Price/Projected FCF is ranked higher than
88% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. AMGN: 1.07 )
Ranked among companies with meaningful Price/Projected FCF only.
AMGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.64  Med: 1.17 Max: 5.96
Current: 1.07
0.64
5.96
Price/DCF (Earnings Based) 0.97
AMGN's Price/DCF (Earnings Based) is ranked higher than
56% of the 18 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. AMGN: 0.97 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.29
AMGN's Price/Median PS Value is ranked lower than
69% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. AMGN: 1.29 )
Ranked among companies with meaningful Price/Median PS Value only.
AMGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.81  Med: 1.42 Max: 4.63
Current: 1.29
0.81
4.63
Price/Peter Lynch Fair Value 0.94
AMGN's Price/Peter Lynch Fair Value is ranked higher than
82% of the 57 Companies
in the Global Biotechnology industry.

( Industry Median: 1.86 vs. AMGN: 0.94 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMGN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.67  Med: 1.58 Max: 3.08
Current: 0.94
0.67
3.08
Price/Graham Number 7.49
AMGN's Price/Graham Number is ranked lower than
87% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. AMGN: 7.49 )
Ranked among companies with meaningful Price/Graham Number only.
AMGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.58  Med: 4.31 Max: 7.68
Current: 7.49
1.58
7.68
Earnings Yield (Greenblatt) (%) 7.70
AMGN's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. AMGN: 7.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 7.30 Max: 13.6
Current: 7.7
3.9
13.6
Forward Rate of Return (Yacktman) (%) 23.63
AMGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
65% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. AMGN: 23.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.9  Med: 16.50 Max: 95.7
Current: 23.63
1.9
95.7

More Statistics

Revenue(Mil) $22156
EPS $ 9.45
Beta1.35
Short Percentage of Float1.35%
52-Week Range $130.09 - 181.81
Shares Outstanding(Mil)752.09

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 22,313 24,388 24,901
EPS($) 10.80 12.33 13.34
EPS without NRI($) 10.80 12.33 13.34

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:CELG, NAS:BIIB » details
Traded in other countries:AMGN.Argentina, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Amgen Inc was incorporated in the State of Delaware on October 31, 1986. It is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics. Its Cardiovascular products include Repatha, Corlanor, Inflammation products include Brodalumab, Nephrology, Oncology products include BLINCYTO, Kyprolis, Neulasta, Rilotumumab, Talimogene laherparepvec, Trebananib, Biosimilars, among others. Its geographic areas of operations include USA, Europe and Canada. Certain raw materials, medical devices and components necessary for the commercial and/or clinical manufacturing of the Company's products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be its only sources for such materials. The Company's sales and marketing forces are mainly located in the United States and Europe. Together with its partners, the Company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. In the United States, the Company sells primarily to pharmaceutical wholesale distributors. The Company's competitors include Teva Pharmaceutical Industries Ltd., Janssen Biotech, Inc., AbbVie Inc., Merck & Company, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly/Bristol-Myers Squibb Company, Merck KGaA, Genentech, Inc., GlaxoSmithKline PLC, Millennium Pharmaceuticals, Inc., and Celgene Corporation. Some of the Company's patents include Neulasta, NEUPOGEN, Enbrel, XGEVA, Prolia, EPOGEN, Aranesp, Sensipar, Mimpara, Kyprolis, Nplate, Vectibix, and BLINCYTO. The Company's business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.
» More Articles for NAS:AMGN

Headlines

Articles On GuruFocus.com
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
Citigroup, Amgen Are Trading With Wide Margin of Safety Mar 30 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Gilead, Johnson & Johnson or Roche? Feb 11 2016 
Plenty of Opportunity to Buy Individual Stocks: John Buckingham Feb 02 2016 
Alan Fournier Sells GM, Buys Molson Coors Brewing Jan 03 2016 
Analyzing Amgen's Dividend Hike Dec 20 2015 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 

More From Other Websites
Analysts Make Major Changes to Top Biotech Ratings May 01 2016
Top Trades: Biotech's brutal week Apr 29 2016
5 way to trade the mixed biotech sector Apr 29 2016
US stocks hit by health care woes but avoid bigger losses Apr 29 2016
US stocks hit by health care woes but avoid bigger losses Apr 29 2016
A Typical Bad First Quarter For Biotech: Leerink Apr 29 2016
What Are Analysts Saying About Q1 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead Apr 29 2016
Amgen (AMGN) Tops Q1 Earnings & Revenues, Ups View Apr 29 2016
Pfizer Earnings Could Highlight Enbrel and Lyrica Sales Decline Apr 29 2016
Edited Transcript of AMGN earnings conference call or presentation 28-Apr-16 9:30pm GMT Apr 29 2016
Amgen posts 1Q sales, profit jumps, raises profit forecasts Apr 28 2016
Amgen posts 1Q sales, profit jumps, raises profit forecasts Apr 28 2016
Amgen profit sails past Street expectations; raises 2016 outlook Apr 28 2016
Q1 Earnings Reports Continue the Deluge: AMZN, GILD, AMGN Apr 28 2016
[$$] Amgen Profit Rises 17%, Guidance Raised Apr 28 2016
Amgen (AMGN) Beats Q1 Earnings Estimates, Raises 2016 Outlook Apr 28 2016
After Hours: Amazon, LinkedIn, Baidu, Expedia Soar, Gilead Flops Apr 28 2016
Amgen Inc Earnings Call scheduled for 5:30 pm ET today Apr 28 2016
Amgen Legacy Drugs Drive Q1 Beat; Gilead Hep C Juggernaut Stumbles Apr 28 2016
AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK